AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30527595 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:80,000 epinephrine
Number of subjects: 106
Study 27102504 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate-adaptive pacing
Number of subjects: 0
Study 27102504 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowering baseline and peak heart rate using ivabradine
Number of subjects: 0
Study 27102504 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronotropic incompetence (CI)
Number of subjects: 0
Study 27102504 — intervention group
Group type: COMPARATOR
Intervention: Fixed-rate pacing
Number of subjects: 0
Study 23551592 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic dilation (PD)
Number of subjects: 92
Study 23551592 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Heller myotomy with partial fundoplication
Number of subjects: 92
Study 24487989 — intervention group
Group type: EXPERIMENTAL
Intervention: Aroma massage performed three times a week for 4 weeks
Number of subjects: 54
Study 24487989 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aroma massage)
Number of subjects: 54
Study 20434403 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate surgery and best medical therapy
Number of subjects: 366
Study 20434403 — intervention group
Group type: COMPARATOR
Intervention: Best medical therapy alone
Number of subjects: 366
Study 18215153 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa (LC) with unchanged dosage
Number of subjects: 39
Study 18215153 — intervention group
Group type: COMPARATOR
Intervention: Levodopa-carbidopa (LC) with reduced dosage by 15-25%
Number of subjects: 39
Study 17030687 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS 301012 (50 to 400 mg, single dose followed by 4-week multiple dosing)
Number of subjects: 36
Study 17030687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 12747268 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg prednisone
Number of subjects: 0
Study 12747268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10824072 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest compression alone
Number of subjects: 520
Study 10824072 — intervention group
Group type: COMPARATOR
Intervention: Chest compression plus mouth-to-mouth ventilation
Number of subjects: 520
Study 8730339 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole (T/S) 2 x 960 mg/day in initial phase WG
Number of subjects: 72
Study 8730339 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole (T/S) 2 x 960 mg/day in generalized WG (group A)
Number of subjects: 72
Study 8730339 — intervention group
Group type: COMPARATOR
Intervention: No further treatment after standard therapy (group B)
Number of subjects: 72
Study 8730339 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole (T/S) plus low-dose prednisone (group C)
Number of subjects: 72
Study 8166061 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg
Number of subjects: 24
Study 8166061 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 10 mg
Number of subjects: 24
Study 8166061 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg
Number of subjects: 24
Study 8166061 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 24
Study 8166061 — intervention group
Group type: COMPARATOR
Intervention: Felodipine and Nifedipine
Number of subjects: 24
Study 8166061 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 24
Study 3400062 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigued state (less than 4 hours of sleep: mean, 2.0 +/- 1.5 hours)
Number of subjects: 42
Study 3400062 — intervention group
Group type: COMPARATOR
Intervention: Rested state (more than 4 hours of sleep: mean, 6.5 +/- 1.0 hours)
Number of subjects: 42
Study 31792945 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP
Number of subjects: 250
Study 31792945 — intervention group
Group type: COMPARATOR
Intervention: R-CVP
Number of subjects: 250
Study 31378995 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 750
Study 31378995 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 750
Study 31378995 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 750
Study 28400411 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 23
Study 28400411 — intervention group
Group type: COMPARATOR
Intervention: Nonobese subjects (control)
Number of subjects: 23
Study 28004493 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydration (IVH)
Number of subjects: 759
Study 28004493 — intervention group
Group type: COMPARATOR
Intervention: Nasogastric hydration (NGH)
Number of subjects: 759
Study 23519371 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 36
Study 23519371 — intervention group
Group type: COMPARATOR
Intervention: Volume-matched saline (placebo)
Number of subjects: 36
Study 22037341 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation program
Number of subjects: 36
Study 20635603 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation under suprascapular nerve block and intraarticular local anesthesia with Methyl prednisolone acetate
Number of subjects: 31
Study 17560702 — intervention group
Group type: EXPERIMENTAL
Intervention: Transactional sex with casual partners
Number of subjects: 1288
Study 17560702 — intervention group
Group type: EXPERIMENTAL
Intervention: Transactional sex with main girlfriends
Number of subjects: 1288
Study 17560702 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of transactional sex
Number of subjects: 1288
Study 17560702 — intervention group
Group type: EXPERIMENTAL
Intervention: Perpetration of gender-based violence
Number of subjects: 1288
Study 17560702 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention interventions
Number of subjects: 1288
Study 15289018 — intervention group
Group type: COMPARATOR
Intervention: Mitoxantrone and etoposide (MVP)
Number of subjects: 80
Study 15289018 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone and etoposide with Cyclosporin A (CsA)
Number of subjects: 80
Study 11318048 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-scale fragments presented early in processing
Number of subjects: 0
Study 11318048 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-scale fragments presented late in processing
Number of subjects: 0
Study 11318048 — intervention group
Group type: EXPERIMENTAL
Intervention: Common feature fragments
Number of subjects: 0
Study 11318048 — intervention group
Group type: EXPERIMENTAL
Intervention: Global-to-local processing
Number of subjects: 0
Study 8790670 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 92
Study 8790670 — intervention group
Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 92
Study 8790670 — intervention group
Group type: COMPARATOR
Intervention: Pyrimethamine-sulfadoxine (P-S)
Number of subjects: 92
Study 1299597 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of amineptine
Number of subjects: 169
Study 1299597 — intervention group
Group type: COMPARATOR
Intervention: 20 mg of fluoxetine
Number of subjects: 169
Study 6367750 — intervention group
Group type: EXPERIMENTAL
Intervention: D-penicillamine alone
Number of subjects: 0
Study 6367750 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (D-penicillamine and hydroxychloroquine)
Number of subjects: 0
Study 6367750 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine therapy
Number of subjects: 0
Study 6367750 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30659035 — intervention group
Group type: EXPERIMENTAL
Intervention: SpO 2 target of 88%-92%
Number of subjects: 2
Study 30659035 — intervention group
Group type: COMPARATOR
Intervention: SpO 2 target of ≥96%
Number of subjects: 2
Study 30659035 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of standard critical care outcome measures between the two intervention groups
Number of subjects: 2
Study 30101851 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat (urate-lowering agent)
Number of subjects: 200
Study 30101851 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 200
Study 25316503 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CPA) 50 mg orally twice a day for 2 weeks before operation and maintained for an extra week postoperatively
Number of subjects: 95
Study 25316503 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CPA)
Number of subjects: 95
Study 24566233 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD implantation for primary prevention of sudden cardiac death (PPSCD)
Number of subjects: 1863
Study 24566233 — intervention group
Group type: COMPARATOR
Intervention: No ICD implantation but had class I indications
Number of subjects: 1863
Study 24566233 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall ICD utilization rate (UR)
Number of subjects: 1863
Study 24566233 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD UR for males
Number of subjects: 1863
Study 24566233 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD UR for females
Number of subjects: 1863
Study 24566233 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD UR for whites
Number of subjects: 1863
Study 24566233 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD UR for blacks
Number of subjects: 1863
Study 22496459 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach program (academic detailing and online tools)
Number of subjects: 3989
Study 19950088 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone 600 mg orally as the initial therapy, with an additional dose of 300 mg after eight hours if needed.
Number of subjects: 81
Study 19950088 — intervention group
Group type: COMPARATOR
Intervention: Quinidine (1 mg digoxin IV followed by oral loading of 400 mg followed by 200 mg every two hours).
Number of subjects: 81
Study 17321397 — intervention group
Group type: EXPERIMENTAL
Intervention: Verisyse IOL implanted under the iris (Group B)
Number of subjects: 27
Study 17321397 — intervention group
Group type: COMPARATOR
Intervention: Verisyse IOL implanted over the iris (Group A)
Number of subjects: 27
Study 15179440 — intervention group
Group type: EXPERIMENTAL
Intervention: COX‐2‐selective inhibitor rofecoxib 25 mg daily for 4 weeks
Number of subjects: 76
Study 15179440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 15179440 — intervention group
Group type: EXPERIMENTAL
Intervention: COX‐2‐selective inhibitor rofecoxib
Number of subjects: 76
Study 11453892 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg twice daily for 7 days)
Number of subjects: 51
Study 11453892 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (60 mg twice daily for 7 days)
Number of subjects: 51
Study 11453892 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol (80 mg twice daily for 7 days)
Number of subjects: 51
Study 11453892 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg twice daily for 7 days)
Number of subjects: 51
Study 11453892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 11453892 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro incubations with propranolol
Number of subjects: 51
Study 11453892 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro incubations with nadolol and metoprolol
Number of subjects: 51
Study 9728825 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol (IV injections)
Number of subjects: 36
Study 9155503 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal (L, 5.5 g mixed fat/meal)
Number of subjects: 12
Study 9155503 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately high-fat meal (M, 33 g mixed fat/meal)
Number of subjects: 12
Study 9155503 — intervention group
Group type: COMPARATOR
Intervention: Moderately high-fat lunch after fasting (NM)
Number of subjects: 12
Study 9155503 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty breakfast
Number of subjects: 12
Study 9155503 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty lunch
Number of subjects: 12
Study 2654171 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE), 100 mg/week
Number of subjects: 30
Study 2654171 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE), 300 mg/week
Number of subjects: 30
Study 2654171 — intervention group
Group type: EXPERIMENTAL
Intervention: 19-nortestosterone decanoate (ND), 100 mg/week
Number of subjects: 30
Study 2654171 — intervention group
Group type: EXPERIMENTAL
Intervention: 19-nortestosterone decanoate (ND), 300 mg/week
Number of subjects: 30
Study 2654171 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 893246 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivmecillinam
Number of subjects: 0
Study 893246 — intervention group
Group type: COMPARATOR
Intervention: Cotrimoxazole
Number of subjects: 0
Study 31932487 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic (LA) exposure
Number of subjects: 180
Study 31932487 — intervention group
Group type: EXPERIMENTAL
Intervention: LA dose
Number of subjects: 180
Study 31932487 — intervention group
Group type: EXPERIMENTAL
Intervention: LA volume
Number of subjects: 180
Study 31165574 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 120
Study 31165574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 27477110 — intervention group
Group type: EXPERIMENTAL
Intervention: OFD with autologous platelet-rich fibrin (PRF)
Number of subjects: 38
Study 27477110 — intervention group
Group type: EXPERIMENTAL
Intervention: OFD with titanium platelet-rich fibrin (TPRF)
Number of subjects: 38
Study 27477110 — intervention group
Group type: COMPARATOR
Intervention: OFD alone
Number of subjects: 38
Study 25588930 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release methylphenidate (MPH-SR) 18 to 54 mg/day for 10 weeks
Number of subjects: 56
Study 25588930 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 10 weeks
Number of subjects: 56
Study 24006963 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Training for Smokers (MTS)
Number of subjects: 55
Study 24006963 — intervention group
Group type: COMPARATOR
Intervention: Interactive Learning for Smokers (ILS)
Number of subjects: 55
Study 24006963 — intervention group
Group type: EXPERIMENTAL
Intervention: MTS
Number of subjects: 55
Study 21801539 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation of treatment benefit using absolute terms
Number of subjects: 393
Study 21801539 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation of treatment harm in relative terms
Number of subjects: 393
Study 19426973 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol
Number of subjects: 100
Study 19426973 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol
Number of subjects: 100
Study 16942416 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (group T) - patients reported three times weekly via a secure Internet site.
Number of subjects: 36
Study 16942416 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical care (group C) - standard care without telemedicine.
Number of subjects: 36
Study 16942416 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (group T)
Number of subjects: 36
Study 16942416 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical care (group C)
Number of subjects: 36
Study 15573017 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender therapy
Number of subjects: 8
Study 15573017 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxing music therapy
Number of subjects: 8
Study 15573017 — intervention group
Group type: COMPARATOR
Intervention: Lemon therapy
Number of subjects: 8
Study 15573017 — intervention group
Group type: COMPARATOR
Intervention: Preferred music therapy
Number of subjects: 8
Study 11388525 — intervention group
Group type: EXPERIMENTAL
Intervention: Large LMA (size 5 in males, size 4 in females)
Number of subjects: 258
Study 11388525 — intervention group
Group type: COMPARATOR
Intervention: Small LMA (size 4 in males, size 3 in females)
Number of subjects: 258
Study 9431839 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg daily for 7 days
Number of subjects: 12
Study 9431839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9431839 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 10 mg single dose
Number of subjects: 12
Study 8493214 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cisplatin combined with ifosfamide and 5-fluorouracil
Number of subjects: 34
Study 3686263 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipemidic acid (Septidron; Ethimed) for 10 days
Number of subjects: 60
Study 3686263 — intervention group
Group type: COMPARATOR
Intervention: Nitrofurantoin for 10 days
Number of subjects: 60
Study 29653338 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive perampanel
Number of subjects: 114
Study 29653338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 27336797 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week body mass-based squat exercise training (100 reps/day, 45 sessions)
Number of subjects: 52
Study 27336797 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 52
Study 27336797 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week body mass-based squat exercise training
Number of subjects: 52
Study 25759248 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention prompt group
Number of subjects: 3213
Study 25759248 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention no-prompt group
Number of subjects: 3213
Study 25759248 — intervention group
Group type: COMPARATOR
Intervention: No intervention control group
Number of subjects: 3213
Study 22749632 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + CT (radiation therapy plus cisplatin, 100 mg/m² i.v. on days 1, 22, and 43)
Number of subjects: 410
Study 22749632 — intervention group
Group type: COMPARATOR
Intervention: RT (radiation therapy, 60 Gy in 6 weeks)
Number of subjects: 410
Study 22749632 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + CT
Number of subjects: 410
Study 22749632 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 410
Study 20601395 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Number of subjects: 150
Study 18327362 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.02 mg)
Number of subjects: 102
Study 18327362 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (0.1 mg)
Number of subjects: 102
Study 18327362 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 102
Study 16676597 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pulse itraconazole (A group)
Number of subjects: 330
Study 16676597 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous terbinafine (B group)
Number of subjects: 330
Study 16676597 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent terbinafine (C group)
Number of subjects: 330
Study 16676597 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance with doctors' order
Number of subjects: 330
Study 16676597 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncompliance with doctors' order
Number of subjects: 330
Study 16676597 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall compliance
Number of subjects: 330
Study 16676597 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing compliance
Number of subjects: 330
Study 12181245 — intervention group
Group type: EXPERIMENTAL
Intervention: Marimastat 5 mg p.o. b.i.d. for 12 months
Number of subjects: 63
Study 12181245 — intervention group
Group type: EXPERIMENTAL
Intervention: Marimastat 10 mg p.o. b.i.d. for 12 months
Number of subjects: 63
Study 12181245 — intervention group
Group type: EXPERIMENTAL
Intervention: Marimastat 5 mg b.i.d. plus tamoxifen
Number of subjects: 63
Study 12181245 — intervention group
Group type: EXPERIMENTAL
Intervention: Marimastat 10 mg b.i.d. plus tamoxifen
Number of subjects: 63
Study 12181245 — intervention group
Group type: EXPERIMENTAL
Intervention: Marimastat 5 mg b.i.d.
Number of subjects: 63
Study 12181245 — intervention group
Group type: EXPERIMENTAL
Intervention: Marimastat 10 mg b.i.d.
Number of subjects: 63
Study 10194832 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabipur vaccine, administered using the 2-1-1 schedule
Number of subjects: 0
Study 10194832 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabipur vaccine
Number of subjects: 0
Study 7594031 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine stress (infused from 5 micrograms/kg/min up to 40 micrograms/kg/min)
Number of subjects: 12
Study 7594031 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine stress
Number of subjects: 12
Study 1941796 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% terconazole cream
Number of subjects: 900
Study 1941796 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8% terconazole cream
Number of subjects: 900
Study 1941796 — intervention group
Group type: COMPARATOR
Intervention: 2.0% miconazole nitrate cream
Number of subjects: 900
Study 7199325 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (Ro 21‐3981, Dormicum)
Number of subjects: 0
Study 7199325 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0
Study 31174535 — intervention group
Group type: EXPERIMENTAL
Intervention: Online yoga (60 min/week)
Number of subjects: 62
Study 31174535 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (maintain normal activity)
Number of subjects: 62
Study 28834553 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (EXE) 10 μg BID
Number of subjects: 176
Study 28834553 — intervention group
Group type: COMPARATOR
Intervention: Metformin (MET) 1000 mg BID
Number of subjects: 176
Study 28834553 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (EXE) during second 12 weeks
Number of subjects: 176
Study 28834553 — intervention group
Group type: COMPARATOR
Intervention: Metformin (MET) during second 12 weeks
Number of subjects: 176
Study 26542510 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of the GRACE risk score (GRS) into routine ACS patient assessment process
Number of subjects: 3000